Research progress on albumin therapy for hepatic encephalopathy
10.3760/cma.j.cn501113-20240427-00232
- VernacularTitle:白蛋白治疗在肝性脑病中的研究进展
- Author:
Zhiling ZHOU
1
;
Dazhi ZHANG
Author Information
1. 重庆医科大学附属第二医院感染科 重庆医科大学感染性疾病分子生物学教育部重点实验室 重庆医科大学病毒性肝炎研究所，重庆 401336
- Keywords:
Albumin;
Hepatic encephalopathy;
Liver cirrhosis;
Cognitive function;
Therapeutic
- From:
Chinese Journal of Hepatology
2024;32(9):861-864
- CountryChina
- Language:Chinese
-
Abstract:
Hepatic encephalopathy (HE) is one of the severe complications of decompensated stage cirrhosis that causes cerebral dysfunction due to hepatic insufficiency and/or portosystemic shunts, and it usually manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. The pathogenesis of HE is complex, although ammonia toxicity, oxidative stress, inflammation, intestinal dysbiosis, and others among them mainly play an important role. The treatment for HE lacks specific drugs, and the current available drugs include non-absorbable disaccharides (lactulose), antibiotics (rifaximin), and other therapies (oral branched-chain amino acids, intravenous injection of L-ornithine-L-aspartic acid, probiotics). Recent research has shown that human albumin is a safe and effective treatment for HE, improving not only cognitive function but also enhancing patients' quality of life.
